When it comes to biotech, both the academic and industry settings are crucial in developing novel medicines. Dr. Brent Cezairliyan has experienced both sides of biotech, first through an academic career exploring bacterial pathogenesis, and now in his administrative role at Octagon Therapeutics. The company, headquartered in Cambridge, Massachusetts, focuses on autoimmune disease treatments. By developing targeted approaches to the inflammatory nature of the immune system, they hope their advances in biotech help future scientists navigate the field for years to come.This content is offered for informational purposes only. The opinions stated in this podcast are that of the speaker and do not constitute or imply an endorsement by Thermo Fisher Scientific.